Immuno-Oncology News

The U.S. Food and Drug Administration will review Genentech‘s Tecentriq
(atezolizumab), in combination with chemotherapy medications Abraxane (nab-
paclitaxel) and carboplatin, as a first-line treatment for metastatic non-
squamous non-small cell ...

Read more

